Gustavo Machado das Neves
Universidade Federal do Rio Grande do Sul
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gustavo Machado das Neves.
Phytotherapy Research | 2000
R. Daudt; G. L. von Poser; Gustavo Machado das Neves; Stela Maris Kuze Rates
An Erratum has been published for this article in Phytotherapy Research 14(8) 2000, 661.
Molecular Diversity | 2017
Luciano Porto Kagami; Gustavo Machado das Neves; Ricardo Pereira Rodrigues; Vinicius da Silva; Vera Lucia Eifler-Lima; Daniel Fábio Kawano
Malaria, a tropical parasitic disease caused by Plasmodium spp., continues to place a heavy social burden, with almost 200 million cases and more than 580,000 deaths per year. Plasmodium falciparum purine nucleoside phosphorylase (PfPNP) can be targeted for antimalarial drug design since its inhibition kills malaria parasites both in vitro and in vivo. Although the currently known inhibitors of PfPNP, immucillins, are orally available and of low toxicity to animals and humans, to the best of our knowledge, none of these compounds has entered clinical trials for the treatment of malaria. Using a pharmacophore-based virtual screening coupled to a consensual molecular docking approach, we identified 59 potential PfPNP inhibitors that are predicted to be orally absorbed in a Caco-2 cell model. Although most of these compounds are predicted to have high plasma protein binding levels, poor water solubility (except for compound 25) and CYP3A4 metabolic stability (except for 4, 7 and 8), four structures (4, 7, 8 and 25) remain as potential leads because of their plausible interaction with a specific hydrophobic pocket of PfPNP, which would confer them higher selectivity for PfPNP over human PNP. Additionally, both predicted Gibbs free energies for binding and molecular dynamics suggest that compound 4 may form a more stable complex with PfPNP than 5
Current Medicinal Chemistry | 2018
Anna Carolina Schneider Alves; Reinaldo Antonio Dias; Luciano Porto Kagami; Gustavo Machado das Neves; Fernando Cidade Torres; Vera Lucia Eifler-Lima; Ivone Carvalho; Carolina de Miranda Silva; Daniel Fábio Kawano
Journal of Molecular Modeling | 2017
Luciano Porto Kagami; Gustavo Machado das Neves; Alan Wilter Sousa da Silva; Rafael Andrade Caceres; Daniel Fábio Kawano; Vera Lucia Eifler-Lima
^{\prime }
Current Drug Discovery Technologies | 2017
Maria Helena Vendruscolo; Gustavo Machado das Neves; Luciano Porto Kagami; Luiz Carlos Rodrigues; Maria Luisa Diehl; Simone Cristina Baggio Gnoatto; Sergio Augusto de Loreto Bordignon; Pedro R.T. Romão; Vera Lucia Eifler Lima; Gilsane Lino von Poser
Current Drug Discovery Technologies | 2016
Gustavo Machado das Neves; Luciano Porto Kagami; Ricardo P. Rodrigues; Vinicius Barreto da Silva; Vera Lucia Eifler-Lima; Daniel Fábio Kawano
′-methylthio-immucillin-H, a potent and selective inhibitor of PfPNP.
Phytotherapy Research | 2000
R. Daudt; G. L. von Poser; Gustavo Machado das Neves; Stela Maris Kuze Rates
For more than 40 years, the fluid mosaic model of cellular membranes has supported our vision of an inert lipid bilayer containing membrane protein receptors that are randomly hit by extracellular molecules to trigger intracellular signaling events. However, the notion that compartmentalized cholesterol- and sphingomyelin-rich membrane microdomains (known as lipid rafts) spatially arrange receptors and effectors to promote kinetically favorable interactions necessary for the signal transduction sounds much more realistic. Despite their assumed importance for the dynamics of ligand-receptor interactions, lipid rafts and biomembranes as a whole remain less explored than the other classes of biomolecules because of the higher variability and complexity of their membrane phases, which rarely provide the detailed atomic-level structural data in X-ray crystallography assays necessary for molecular modeling studies. The fact that some alkylphospholipids (e.g. edelfosine: 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) selectively induce the apoptotic death of cancer cells by recruiting Fas death receptors and the downstream signaling molecules into clusters of lipid rafts suggests these potential drug targets deserve a more in-depth investigation. Herein, we review the structure of lipid rafts, their role in apoptotic signaling pathways and their potential role as drug targets for the treatment of cancer.
Current Medicinal Chemistry | 2015
Patrícia Frasson Corbelini; Fabrício Figueiró; Gustavo Machado das Neves; Saulo Fernandes Andrade; Daniel Fábio Kawano; Ana Maria Oliveira Battastini; Vera Lucia Eifler-Lima
To speed up the drug-discovery process, molecular dynamics (MD) calculations performed in GROMACS can be coupled to docking simulations for the post-screening analyses of large compound libraries. This requires generating the topology of the ligands in different software, some basic knowledge of Linux command lines, and a certain familiarity in handling the output files. LiGRO—the python-based graphical interface introduced here—was designed to overcome these protein–ligand parameterization challenges by allowing the graphical (non command line-based) control of GROMACS (MD and analysis), ACPYPE (ligand topology builder) and PLIP (protein-binder interactions monitor)—programs that can be used together to fully perform and analyze the outputs of complex MD simulations (including energy minimization and NVT/NPT equilibration). By allowing the calculation of linear interaction energies in a simple and quick fashion, LiGRO can be used in the drug-discovery pipeline to select compounds with a better protein-binding interaction profile. The design of LiGRO allows researchers to freely download and modify the software, with the source code being available under the terms of a GPLv3 license from http://www.ufrgs.br/lasomfarmacia/ligro/.
MedChemComm | 2018
Itamar Luís Gonçalves; Liliana Rockenbach; Gustavo Machado das Neves; Gabriela Göethel; Fabiana Nascimento; Luciano Porto Kagami; Fabrício Figueiró; Gabriel Oliveira de Azambuja; Amanda de Fraga Dias; Andressa Amaro; Lauro Mera de Souza; Ivan da Rocha Pitta; Daiana Silva Ávila; Daniel Fábio Kawano; Solange Cristina Garcia; Ana Maria Oliveira Battastini; Vera Lucia Eifler-Lima
BACKGROUND Leishmaniasis reaches millions of people around the world. The control of the disease is difficult due to the restricted access to the diagnosis and medication and the low adherence to the treatment. Thus, more efficient drugs are need and natural products are good alternatives. Iridoids, natural products with reported leishmanicidal activity, can be exploited for the development of anti-Leishmania drugs. The aim of this study was to isolate and to investigate the in vitro activity of iridoids against Leishmania amazonensis and to compare the activity in silico of these compounds with those reported as active against this parasite. METHODS Iridoids were isolated by chromatographic methods. The in vitro activity of asperuloside (1) and geniposide (2) from Escalonia bifida, galiridoside (3) from Angelonia integerrima and theveridoside (4) and ipolamiide (5) from Amphilophium crucigerum was investigated against promastigote forms of Leishmania amazonensis. Molecular modeling studies of 1-5 and iridoids cited as active against Leishmania spp. were performed. RESULTS compounds 1-5 (5-100 μM) did not inhibit the parasite. Physicochemical parameters predicted for 1-5 did not show differences compared to those described in literature. The SAR and the pharmacophoric model confirmed the importance of maintaining the cyclopentane[C]pyran ring of the iridoid, of oxygen-linked substituents at the C1 and C6 positions and of bulky substituents attached to the iridoid ring to present leishmanicidal activity. CONCLUSION The results obtained in this study indicate that iridoids are a promising group of secondary metabolites and should be further investigated in the search for new anti-Leishmania drugs.
Tetrahedron Letters | 2018
Itamar Luís Gonçalves; Leonardo Davi; Liliana Rockenbach; Gustavo Machado das Neves; Luciano Porto Kagami; Rômulo Faria Santos Canto; Fabrício Figueiró; Ana Maria Oliveira Battastini; Vera Lucia Eifler-Lima
BACKGROUND Guanine phosphoribosyltransferase (GPRT) is a very attractive target for the development of new drugs against G. lamblia because of its critical role in the synthesis of DNA and RNA. Herein we report the use of in silico approaches to identify potential G. lamblia GPRT inhibitors. METHODS Analyses of the binding site of the enzyme accomplished through the use of several methods allowed the construction of a pharmacophore model, which was screened against a database of commercial substances. The resulting retrieved compounds were then screened against GPRT by consensus docking with two different methods, and the top 10% scored compounds had their poses visually inspected. Root Mean Square Deviation (RMSD) values ≤ 2.0 Å were used to define a consensual pose while RMSD values between 2 and 3 Å defined a partial consensus. Main toxicity endpoints were predicted through substructural analyses. RESULTS From the 1,230 compounds retrieved in the pharmacophore-based screening, eleven had their binding modes consensually ascribed by the docking methods, suggesting a better selectivity for the parasite enzyme in comparison to the human counterpart by avoiding steric bumps with a flexible loop in the human enzyme binding site. One compound, ZINC38139588, was predicted to be totally devoid of toxicity, being perhaps the most promising of this series. CONCLUSION Through rigorously validated docking protocols, we predicted the binding mode of these compounds in the GPRT binding site. The use of a consensus docking strategy yielded more reliable predictions of the binding modes to guide the future biological assays.